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In 1968 it was shown by Schou that longterm lithium therapy in psychiatric
patients may cause hypothyroidism or goiter. Lithium is frequently used for
manic-depressi'" 'e diseases (i.e. bipolar depressions) and recurrent (i.e. unipolar)
depressions. further to be called 'affective disorders'. The influence of l i thium-
carbonate on the function of the hypothalamic-pituitary-thyroid axis in
patients rvith affective disorders, thyrotoxicosis and hypothyroidism is discussed
in th is  thesis .
The a im of  the study was:
l. To estabiish the frequency and nature of l i thium induced changes on the
function of the hypothalamic-pituitary-thyroid axis.
2. To explore the possibil i ty of detecting early dysfunction of the thyroid in
patients on longterm lithiumcarbonate.
3. To answer the question, whether there is a place for clinical use of l i thium-
therapy in the treatment of thyrotoxicosis.
The survey of the l iterature in chapter I starts with a description of t l ie discovery
and use of l i thium. Attention is paid to its pharmacology. The possible mode of
action in patients with affective disorders is discussed : l i thiurn can affect sy rraptic
t ransmiss ion,  nerve exci tat ion,  and neuronal  metabol ism. However,  i t  is  not
clear, whether these effects are produced by alterations of ion transport or
distribution. by inhibit ion of adenylcyclase mediated responses or by more
direct interference u'ith neuronal metabolism. Common side effects and com-
plications, as weli as toxicology and treatment associated with longterm li-
thium therapy, are described. The thyroid physiology is reviewed and tlte possi-
b le mode of  act ion on the thyro id homeostasis  is  considered.
The groups of patients studied and the methods used for evaluation of the
function of the hypothalamic-pituitary-thyroid axis are presented ir-r chapter II.
The patients were divided in three categories (A, B and C). The categor,es are
subdivided.
Category A consists of clinicaily euthyroid patients with affective disorders on
maintenance lithiumcarbonate. TRH tests were performed before, and during
2 and 6 weeks after starting l ithium therapf in 7 patients (category A-1), before
and at 3-monthly intervals during therapy, for a longer period of t ime in l3
patients (categorl ' A-2), and finally during l ithium treatment and after 2, 4
and 6 weeks after discontinuation of the medication (category A-3). Category
A-4, consisting of all patients of the categories A-1, A-2, A-3 and some others,
shows the incidence of hypothyroidism, goiter or both conditions in 46 patients,
who were seen in a period of 28 months. Thirty of these patients, who were
seen at 3-monthly intervals were divided in two subgroups A-4a (22 patients)
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and A-4b (8 patients), according to a normal or raised basal TSH level, re-
spectively.
The second group studied (category B) consists of 26 thyrotoxic patients, of
whom four were contau'tinated with exogeuous iodine (categor,v B-2).
Seven patients with hypothyroidism. of whom one patient *.as athl,reotic,
form category C.
The first part of chapter III deals with the resulrs of TRH tests before, during
and after longterm lithium therapy in patients with alTective disorders (category
A-1,  A-2 and A-3) .  I t  appears that  l i th iumcarbonate,  at  serum l i th ium levels
vary ing f rom 0,4 to 1.2 mEql l ,  has a rapid inhib i tory ef fect  on thy ' ro id hormone
release. This leads to an init ial decrease of free Tr (FTlF) and free T3 (FT3F).
calculated according to Hamada (1970).  Meanwhi le a new equi l ibr ium isset to
maintain thyroid honreostasis, as is expressed bY a permanellt increased TSH
response to TRH and often by a raised basal TSH. resulting in practically
normal thyroid hormone levels.
The second part of this chapter reports that two (4.4%) of the 46 parients
(category A-4) on maintenance lithium therapy, developed a goiter, four (8.7 ,",,)
became clinically hypothyroid, whereas eleven (23.9 %) had a rransient or
permanent increase in basal TSH levei. The group rvith elevated basal TSH
levels (A-4b) showed a remarkabll, high incidence of rhyroid antibodies (50 %\.
It appears that individuals on longterm lithium therapy with a so-called ' lorv
thyroid reserve' are predestined to develop h1.'pothyroidism. History, increased
basal TSH levels, the presence of antibodies and later on, the clinical picture
have to draw our attention to the possibil i ty of imminent hypothyroidism.
The effect of l i thium on the hypothalamic-pituitary-thyroid axis is reversible;
discontinuation of therapy normalizes the TSH response wtthin 6 weeks. The
induced changes seem to be proportional to the serum lithium levels. as can be
seen from two case histories. It is concluded that a thorough clinical and
laboratory investigation should pleceed init iation of l i thium therapy and should
be pursued throughout the course of the treatment.
The results of the treatment with l ithiumcarbonate of thyrotoxic patients
(category B) is the sr-rbject of chapter IV. It appears that l i thiurn, at serum
lithiurn levels of 0,8 mEq/1, almost completely blocks the thyroidal hormone
release during the first 6 days of therapy. However, the TSH response to TRH
does not normalize. Four thyrotoxic patients \\ 'ere prepared with l ithium-
carbonate and underwent subtotal thyroidectomy without complications.
Five patients were trealed with maintenance lithium therapy. After init ial
euthyroidism. four relapsed. This is probably due to an escape phenomenon,
caused by thyroidai iodine pooling. One patient remained clinically euthyroid
for over a year. However his r31I uptake had normalized.
The result of l i thiurr treatmenr in patients with thyrotoxicosis and iodine con-
tamination, caused by contrast mediums. rvas less favourable. Holever, com-
bination treatment with thionamides, which inhibits the iodine organification.
may prove to be useful by preventing iodine pooling.
r3rl uptake tests before and during l ithium therapy shorv that iodine is retained
by the thyroid. This means that l i thiumcarbonate might be a useful adjunct to
'3rI therapy, particularly in case of metastatic thyroid malignancy, to diminish
the total body radiation.
In conclusion, l i thiumcarbonate seems to be useful to restore euthyroidism
rapidly, although the side effects have to be taken into consideration. ln contrast
to iodine, l i thium therapy does not interfere with diagnostic measurements of
thyroid function, which is an advantage.
Chapter V describes the influence of l i thium in patients with hypothyroidism
(category C) studied, to derive additional information concerning the action of
l ithium on the hypothalamic-pituitary axis. The best approach is to perform a
study in a totally thyroidectomized individual. An athyreotic patient, who had
not been taking his replacement therapy for at least 3 months, was treated with
lithiumcarbonate for a week. At serum lithium levels of 0,7 mEq/l a direct
rregative effect of l i thium on the TSH secretion is documented.
Subsequently, a group of 6 patients with hypothyroidism was studied. The
results show that as long as l ithium is able to decrease thyroid hormone produc-
tion, one cannot exclude its indirect positive influence on the TSH production by
the pituitary. Thus, in hypothyroid patients with residual thyroid function, the
thyroidal hormone release inhibit ion by l ithiurn provides an indirect positive
effect, which obscures l ithium's direct negative effect on TSH secretion.
Some years ago lithiumsalts became popular temporarily, as a salt substitute in
sodium restricted diets. Soon, horvever, because of reported toxic side effects
their use rvas stopped abruptly. Nowadays, l i thiumcarbonate is frequently used
in some groups of psychiatric patients. Better knowledge of l i thium's properties
enables us to prevent undesirable side effects. Moreover, one of these side effects
can be useful in the treatment of patients with thyroid diseases, e.g. thyrotoxi-
cosis  and thvro id mal isnancv.
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